Shilpa Medicare’s Jadcherla Facility – An Analysis

Shilpa Medicare recently received a notice from the U.S. Food and Drug Administration (USFDA) regarding its facility in Jadcherla, Telangana. This means the USFDA found some issues during an inspection. The inspection, which took place from November 12th to 21st, 2025, revealed eight observations – that’s like finding eight things that need fixing.

Key Points

• USFDA found eight observations at Shilpa’s Jadcherla plant.
• These observations are new and haven’t been repeated before.
• The plant makes medicines for global markets like the US & Europe.
• US sales from this plant are currently a small part of Shilpa’s business.
• Shilpa Medicare is responding to the USFDA’s findings quickly.
• Company profits and revenue have significantly increased recently.

This facility makes a variety of medicines, including injectable drugs, tablets, and capsules. These products are then sold in the United States, Europe, and other countries around the world. Importantly, the USFDA’s findings are for new observations, meaning this isn’t a problem Shilpa Medicare has faced before.

Shilpa Medicare emphasizes that sales from this particular plant are currently a small part of their overall business. Specifically, US sales account for less than 1% of their total sales for the first half of the financial year ending June 2026, and less than 5% for the full financial year ending March 2025. This suggests a shift in their market focus.

The Jadcherla facility has approvals from major regulatory agencies globally, including the European Medicines Agency (EMA), Health Canada, Anvisa (Brazil), and the Therapeutic Goods Administration (TGA) in Australia. This demonstrates the quality and standards of the facility.

Recent financial results show a strong recovery for Shilpa Medicare. Their consolidated net profit jumped by 145.7% to Rs 44.07 crore in the second quarter of the financial year 2026 (Q2 FY26), compared to Rs 17.94 crore in the previous quarter (Q2 FY25). Revenue also increased by 7.6% year-over-year to Rs 369.97 crore for the period ending September 30th, 2025.

“Shilpa Medicare is committed to addressing the USFDA’s observations promptly and effectively to maintain its regulatory compliance.”